Fingolimod to protect kidney function after kidney transplant
Treatments studied
Part of Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting your first or second kidney transplant (and you’re 18 to 65).
- You can take medicines by mouth and agree to follow all study visits and instructions for the full study.
- You agree to stop certain blood thinners around kidney biopsy time (including aspirin), and avoid grapefruit products for the study.
- You have acceptable blood test and antibody results (reactive antibodies under 50%) and can safely have the required heart and health testing.
- If you can get pregnant: you must have a negative pregnancy test and use two effective birth control methods during the study and for 6 weeks after the last related dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This study tests whether a medicine called finerenone can help protect kidney transplants from further damage. People who have had a kidney transplant and have protein in their urine may benefit from this treatment.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
Hear when a new Kidney Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.